

The Goodman Cancer Research Centre Seminar Series 2016-17

Invited Seminar Speaker

Wednesday, March 22, 2017
4:00 PM – 5:00 PM
McIntyre Medical Building
Palmer Amphitheatre, Room 522



Robert Day, Ph.D.
Professeur
Institut de pharmacologie de Sherbrooke
Department de chirurgie / Service d'urologie

A novel therapeutic approach for advanced prostate cancer

The primary therapies for prostate cancer are surgery and radiation. However, recurrence is a problem for many men and once the cancer has spread, the outlook is very poor. Prostate cancer patients benefit from targeted therapies that affect androgens. While these targeted therapies usually work initially, subsequently tumour cells adapt to resist therapy, leaving patients with few options. Thus there is an urgent need for novel non-androgen targeted therapies. In this conference, I will discuss our novel findings that provide evidence for an entirely new therapeutic strategy based on the inhibition of an enzyme known as PACE4. We have developed a potent lead compound, named C23, that is now ready for preclinical studies and shows very promising results in various animal models. In advanced prostate cancer, we can easily envisage a co-therapeutic approach using C23 with chemotherapy or anti-androgens to have synergistic effects and improve patient outcomes.

STUDENTS: If you would like to attend a lunch with Dr. Day, please send an email to: leah.donnelly@mcgill.ca

EVERYONE IS WELCOME

BIENVENUE A TOUS



MANDATORY FOR GRADUATE
STUDENTS / OBLIGATOIRE
POUR ÉTUDIANTS DIPLÔMÉS